The Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) for depemokimab for asthma with type 2 inflammation and chronic rhinosinusitis with nasal polyps ...
Chronic sinusitis with nasal polyps (CRSwNP) accounts for 20 to 33 percent ... a heavy social and economic burden. Results from a drug trial showed AstraZeneca and Amgen's new drug Tezspire ...
Hosted on MSN1mon
EMA Accepts GSK's Filing for Depemokimab in Two Respiratory DiseasesWith regard to the asthma indication, the GSK submission seeks approval for the drug in individuals aged 12 years and older. Concerning CRSwNP, GSK intends to secure approval in adults.
AZ is hoping that Fasenra (benralizumab) could join rival drugs from Sanofi/Regeneron and GlaxoSmithKline as approved therapies for chronic rhinosinusitis with nasal polyps (CRSwNP) that have been ...
TEZSPIRE was generally well tolerated in patients with CRSwNP and had a safety profile consistent with its approved severe asthma indication.The most frequently reported adverse events for ...
A Prescription Drug User Fee Act target date of December ... type 2 inflammation and chronic rhinosinusitis with nasal polyps (CRSwNP). Depemokimab is an ultra-long acting biologic with high ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback